Combined Treatment of Ketogenic Diet and Propagermanium Reduces Neuroinflammation in Tay-Sachs Disease Mouse Model

Overview

Journal Metab Brain Dis

Publisher Springer

Specialties Endocrinology
Neurology

Date 2025 Feb 28

PMID 40019557

Authors

Orhan Kerim Inci

Volkan Seyrantepe

Affiliations

Soon will be listed here.

Abstract

Tay-Sachs disease is a rare lysosomal storage disorder caused by β-Hexosaminidase A enzyme deficiency causing abnormal GM2 ganglioside accumulation in the central nervous system. GM2 accumulation triggers chronic neuroinflammation due to neurodegeneration-based astrogliosis and macrophage activity with the increased expression level of Ccl2 in the cortex of a recently generated Tay-Sachs disease mouse model Hexa-/-Neu3-/-. Propagermanium blocks the neuroinflammatory response induced by Ccl2, which is highly expressed in astrocytes and microglia. The ketogenic diet has broad potential usage in neurological disorders, but the knowledge of the impact on Tay-Sach disease is limited. This study aimed to display the effect of combining the ketogenic diet and propagermanium treatment on chronic neuroinflammation in the Tay-Sachs disease mouse model. Hexa-/-Neu3-/- mice were placed into the following groups: (i) standard diet, (ii) ketogenic diet, (iii) standard diet with propagermanium, and (iv) ketogenic diet with propagermanium. RT-PCR and immunohistochemistry analyzed neuroinflammation markers. Behavioral analyses were also applied to assess phenotypic improvement. Notably, the expression levels of neuroinflammation-related genes were reduced in the cortex of 140-day-old Hexa-/-Neu3-/- mice compared to β-Hexosaminidase A deficient mice (Hexa-/-) after combined treatment. Immunohistochemical analysis displayed correlated results with the RT-PCR. Our data suggest the potential to implement combined treatment to reduce chronic inflammation in Tay-Sachs and other lysosomal storage diseases.

References

Cougnoux A, Drummond R, Collar A, Iben J, Salman A, Westgarth H . Microglia activation in Niemann-Pick disease, type C1 is amendable to therapeutic intervention. Hum Mol Genet. 2018; 27(12):2076-2089. PMC: 5985727. DOI: 10.1093/hmg/ddy112. View

Tsukuda K, Mogi M, Iwanami J, Min L, Jing F, Oshima K . Irbesartan attenuates ischemic brain damage by inhibition of MCP-1/CCR2 signaling pathway beyond AT₁ receptor blockade. Biochem Biophys Res Commun. 2011; 409(2):275-9. DOI: 10.1016/j.bbrc.2011.04.142. View

He S, Liu R, Li B, Huang L, Fan W, Tembachako C . Propagermanium, a CCR2 inhibitor, attenuates cerebral ischemia/reperfusion injury through inhibiting inflammatory response induced by microglia. Neurochem Int. 2019; 125:99-110. DOI: 10.1016/j.neuint.2019.02.010. View

Jang J, Kim S, Lee J, Lee S, Son H, Choe W . Molecular Mechanisms of Neuroprotection by Ketone Bodies and Ketogenic Diet in Cerebral Ischemia and Neurodegenerative Diseases. Int J Mol Sci. 2024; 25(1). PMC: 10779133. DOI: 10.3390/ijms25010124. View

Sango K, Yamanaka S, Hoffmann A, Okuda Y, Grinberg A, Westphal H . Mouse models of Tay-Sachs and Sandhoff diseases differ in neurologic phenotype and ganglioside metabolism. Nat Genet. 1995; 11(2):170-6. DOI: 10.1038/ng1095-170. View

Reichel C, Rehberg M, Lerchenberger M, Berberich N, Bihari P, Khandoga A . Ccl2 and Ccl3 mediate neutrophil recruitment via induction of protein synthesis and generation of lipid mediators. Arterioscler Thromb Vasc Biol. 2009; 29(11):1787-93. DOI: 10.1161/ATVBAHA.109.193268. View

Stumpf S, Berghoff S, Trevisiol A, Spieth L, Duking T, Schneider L . Ketogenic diet ameliorates axonal defects and promotes myelination in Pelizaeus-Merzbacher disease. Acta Neuropathol. 2019; 138(1):147-161. PMC: 6570703. DOI: 10.1007/s00401-019-01985-2. View

Denny C, Heinecke K, Kim Y, Baek R, Loh K, Butters T . Restricted ketogenic diet enhances the therapeutic action of N-butyldeoxynojirimycin towards brain GM2 accumulation in adult Sandhoff disease mice. J Neurochem. 2010; 113(6):1525-35. DOI: 10.1111/j.1471-4159.2010.06733.x. View

Jeyakumar M, Thomas R, Elliot-Smith E, Smith D, van der Spoel A, dAzzo A . Central nervous system inflammation is a hallmark of pathogenesis in mouse models of GM1 and GM2 gangliosidosis. Brain. 2003; 126(Pt 4):974-87. DOI: 10.1093/brain/awg089. View

10.

Klein R, Lin E, Zhang B, Luster A, Tollett J, Samuel M . Neuronal CXCL10 directs CD8+ T-cell recruitment and control of West Nile virus encephalitis. J Virol. 2005; 79(17):11457-66. PMC: 1193600. DOI: 10.1128/JVI.79.17.11457-11466.2005. View

11.

Nilsson M, Crozier M, Di Carlo A, Xhuti D, Manta K, Roik L . Nutritional co-therapy with 1,3-butanediol and multi-ingredient antioxidants enhances autophagic clearance in Pompe disease. Mol Genet Metab. 2022; 137(1-2):228-240. DOI: 10.1016/j.ymgme.2022.06.001. View

12.

Yao Y, Tsirka S . Monocyte chemoattractant protein-1 and the blood-brain barrier. Cell Mol Life Sci. 2013; 71(4):683-97. PMC: 3946874. DOI: 10.1007/s00018-013-1459-1. View

13.

Fyke Z, Johansson R, Scott A, Wiley D, Chelsky D, Zak J . Reduction of neuroinflammation and seizures in a mouse model of CLN1 batten disease using the small molecule enzyme mimetic, N-Tert-butyl hydroxylamine. Mol Genet Metab. 2024; 143(1-2):108537. PMC: 11473239. DOI: 10.1016/j.ymgme.2024.108537. View

14.

Xu J, Dong H, Qian Q, Zhang X, Wang Y, Jin W . Astrocyte-derived CCL2 participates in surgery-induced cognitive dysfunction and neuroinflammation via evoking microglia activation. Behav Brain Res. 2017; 332:145-153. DOI: 10.1016/j.bbr.2017.05.066. View

15.

Vitner E, Farfel-Becker T, Eilam R, Biton I, Futerman A . Contribution of brain inflammation to neuronal cell death in neuronopathic forms of Gaucher's disease. Brain. 2012; 135(Pt 6):1724-35. DOI: 10.1093/brain/aws095. View

16.

Pandey M . Exploring Pro-Inflammatory Immunological Mediators: Unraveling the Mechanisms of Neuroinflammation in Lysosomal Storage Diseases. Biomedicines. 2023; 11(4). PMC: 10135900. DOI: 10.3390/biomedicines11041067. View

17.

Horii Y, Iniwa T, Onitsuka M, Tsukimoto J, Tanaka Y, Ike H . Reversal of neuroinflammation in novel GS model mice by single i.c.v. administration of CHO-derived rhCTSA precursor protein. Mol Ther Methods Clin Dev. 2022; 25:297-310. PMC: 9062439. DOI: 10.1016/j.omtm.2022.04.001. View

18.

Stafstrom C, Rho J . The ketogenic diet as a treatment paradigm for diverse neurological disorders. Front Pharmacol. 2012; 3:59. PMC: 3321471. DOI: 10.3389/fphar.2012.00059. View

19.

Kossoff E, Hartman A . Ketogenic diets: new advances for metabolism-based therapies. Curr Opin Neurol. 2012; 25(2):173-8. PMC: 4002181. DOI: 10.1097/WCO.0b013e3283515e4a. View

20.

Kalkonde Y, Morgan W, Sigala J, Maffi S, Condello C, Kuziel W . Chemokines in the MPTP model of Parkinson's disease: absence of CCL2 and its receptor CCR2 does not protect against striatal neurodegeneration. Brain Res. 2006; 1128(1):1-11. DOI: 10.1016/j.brainres.2006.08.041. View